Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp, filed a Form 4 on September 10, 2026, disclosing the sale of common stock on September 8, 2026, in connection with the vesting of Restricted Stock Units.

Key Highlights

  • Shares sold: 2,302 shares of Twist Bioscience Corp common stock were disposed of on September 8, 2026.
  • Sale price: The shares were sold at $122.624 per share.
  • Purpose: According to the filing, the sale was mandated by the issuer to cover tax withholding obligations tied to RSU vesting and does not represent a discretionary trade by the reporting person.
  • Remaining direct ownership: Following the transaction, Leproust directly held 768,427 shares of common stock.
  • Options held: The filing reports several employee stock options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering a combined 404,948 shares underlying those options.
  • Ticker and exchange: Twist Bioscience Corp trades as NASDAQ:TWST.

Leproust Tax-Withholding Sale and Option Holdings at Twist Bioscience

According to the Form 4 filed with the SEC on September 10, 2026, Emily M. Leproust, who serves as Chief Executive Officer and Director of Twist Bioscience Corp (NASDAQ:TWST), disposed of 2,302 shares of common stock on September 8, 2026, at a price of $122.624 per share. The filing states that these sales "are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."

Following the reported transaction, Leproust's direct beneficial ownership stood at 768,427 shares of common stock, according to the filing. The Form 4 was signed by Kendra Fox as Attorney-in-Fact for Emily M. Leproust on September 10, 2026.

The filing also discloses several employee stock options held directly by Leproust. These include options with exercise prices of $8.82 covering 75,439 shares (expiring September 28, 2027), $26.66 covering 133,269 shares (expiring November 18, 2028), $23.33 covering 131,290 shares (expiring October 23, 2029), and $67.85 covering 64,950 shares (expiring August 31, 2030). The $67.85 options are described in the filing as performance stock options granted on September 1, 2020, that vested and became exercisable on December 19, 2022, following the reporting person having met the applicable performance criteria.

What Was Disclosed

The filing reports a mandatory tax-withholding sale of 2,302 common shares at $122.624 per share by Twist Bioscience's CEO on September 8, 2026, leaving her with 768,427 directly held shares and several employee stock options.